Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. news centers on the company's completed plan of arrangement, under which XenoTherapeutics acquired all issued and outstanding common shares, and the related removal of ESSA common stock from Nasdaq listing and Section 12(b) registration. Recurring updates also address shareholder voting matters, material agreements, common-share, option and warrant disclosures, governance, risk factors, clinical or regulatory disclosures, and operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company, announced its participation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 2:00 p.m. Eastern Time in Toronto, Ontario. Key executives, including President and CEO David R. Parkinson, COO Peter Virsik, and CFO David S. Wood, will engage in one-on-one meetings with investors.
The conference connects U.S. and Canadian investors with updates on the Canadian healthcare sector and features both presentations and private meetings with prominent companies. A live webcast of ESSA's presentation will be available on the company’s website, with an archived version accessible for 90 days thereafter.